PMID- 23602035
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20220408
IS  - 1557-8615 (Electronic)
IS  - 0883-9441 (Linking)
VI  - 28
IP  - 5
DP  - 2013 Oct
TI  - Patients with New York Heart Association class III heart failure may benefit with 
      high flow nasal cannula supportive therapy: high flow nasal cannula in heart 
      failure.
PG  - 741-6
LID - S0883-9441(13)00050-6 [pii]
LID - 10.1016/j.jcrc.2013.02.007 [doi]
AB  - PURPOSE: High flow nasal cannula (HFNC) may decrease preload being associated 
      with beneficial hemodynamic and respiratory effects in adults with heart failure. 
      METHODS: This is a sequential intervention prospective study including 10 adults 
      with New York Heart Association (NYHA) class III and left ventricle ejection 
      fraction 45% or less. High flow gas was administered (fraction of inspired 
      oxygen, 0.21) through nasal cannula (Optiflow(TM); Fisher & Paykel, Auckland, New 
      Zealand). Sequential echocardiographies were performed at baseline, using HFNC 
      with 20 lpm and 40 lpm and post-HFNC. A reduction greater than 20% in the 
      estimated inspiratory collapse of the inferior vena cava (IVC) from baseline was 
      considered clinically significant. RESULTS: Ten patients were included, with 
      median age of 57 (44-65) years; 6 (60%) were female, and 8 (80%) had dilated 
      cardiomyopathy. Median IVC inspiratory significantly (P<.05) decreased from 
      baseline (37%) to HFNC with 20 lpm (28%) and HFNC with 40 lpm (21%), representing 
      mean attributable reductions of 20% (95% confidence interval, 6-55) and 53% (95% 
      confidence interval, 36-67) from baseline. Changes in the IVC inspiratory 
      collapse were reversible after HFNC withdrawal. Respiratory rate was 
      significantly reduced from 23 breaths per minute at baseline to 17 breaths per 
      minute at HFNC with 20 lpm and 13 breaths per minute at HFNC with 40 lpm. In 
      contrast, no significant changes in other echocardiographic or clinical variables 
      were documented. CONCLUSION: These findings suggest that patients with NYHA class 
      III heart failure may benefit with HFNC supportive therapy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Roca, Oriol
AU  - Roca O
AD  - Critical Care Department and CRIPS investigators, Vall d'Hebron University 
      Hospital, Institut de Recerca Vall d'Hebron - VHIR, Universitat Autonoma 
      Barcelona, Barcelona, Spain; CibeRes (Ciber de Enfermedades Respiratorias), 
      Instituto de Salud Carlos III, Madrid, Spain.
FAU - Perez-Teran, Purificacion
AU  - Perez-Teran P
FAU - Masclans, Joan R
AU  - Masclans JR
FAU - Perez, Lourdes
AU  - Perez L
FAU - Galve, Enrique
AU  - Galve E
FAU - Evangelista, Arturo
AU  - Evangelista A
FAU - Rello, Jordi
AU  - Rello J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130416
PL  - United States
TA  - J Crit Care
JT  - Journal of critical care
JID - 8610642
SB  - IM
CIN - J Crit Care. 2014 Jun;29(3):466-7. PMID: 24602998
CIN - J Crit Care. 2014 Jun;29(3):465. PMID: 24636723
MH  - Adult
MH  - Aged
MH  - Echocardiography
MH  - Female
MH  - Heart Failure/classification/diagnostic imaging/*therapy
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Inhalation Therapy/*methods
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Heart failure
OT  - High flow nasal cannula
EDAT- 2013/04/23 06:00
MHDA- 2014/05/28 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/02 00:00 [received]
PHST- 2013/01/17 00:00 [revised]
PHST- 2013/02/11 00:00 [accepted]
PHST- 2013/04/23 06:00 [entrez]
PHST- 2013/04/23 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - S0883-9441(13)00050-6 [pii]
AID - 10.1016/j.jcrc.2013.02.007 [doi]
PST - ppublish
SO  - J Crit Care. 2013 Oct;28(5):741-6. doi: 10.1016/j.jcrc.2013.02.007. Epub 2013 Apr 
      16.